Glepaglutide for short bowel syndrome
Glepaglutide is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome (SBS). The trial investigates the potential for less than once-daily dosing.
Many people with short bowel syndrome (SBS) are dependent on frequent intake of intravenous fluids and nutrition delivered through a central catheter.
They experience a number of serious and lifethreatening complications associated with their disease and treatment, such as shortened life expectancy as well as high risk of sepsis and other infections, blood clots, liver damage and renal impairment.
Glepaglutide will progress to Phase 3 in 2018. Orphan drug designation has been granted in the U.S.
My worst fear was to become what I am today: a short bowel patient
Marianne was diagnosed with cancer of the small intestine and became a short bowel patient. Today, she manages to live a life on home parenteral nutrition and works as a pastor.